Tag: chronic low back pain
Mainstay announces positive outcomes in “landmark” restorative neurostimulation trial
Mainstay Medical has announced the publication of positive one-year primary assessment results from the RESTORE randomised clinical trial evaluating ReActiv8 for the treatment of...
SynerFuse appoints Rohan Lall as chief medical officer
SynerFuse has announced the appointment of Rohan Lall (M Health Fairview Neurosurgery, Princeton, USA) as the company’s chief medical officer. The appointment was effective...
SynerFuse completes enrolment in proof-of-concept study
SynerFuse has announced that it has completed enrolment in its proof-of-concept study to evaluate the safety and tolerability of the Electric Transforaminal Lumbar Interbody...
Boston Scientific to expand neuromodulation portfolio with Relievant Medsystems acquisition
Boston Scientific Corporation has today announced it has entered into a definitive agreement to acquire Relievant Medsystems—a privately held medical technology company that has...
Mainstay Medical announces completion of US enrolment in RESTORE clinical trial
Mainstay Medical has announced the completion of enrolment in its RESTORE randomised clinical study of ReActiv8 for the treatment of intractable chronic low back...
First SynerFuse procedure performed by solo surgeon in two-level spinal fusion...
SynerFuse has announced that—for the first time in the world, it claims—a solo spine surgeon has performed the SynerFuse procedure in a two-level spinal...
Cochrane Library urged to retract and revise recent SCS review over...
Pain physicians have urged the Cochrane Library to retract and revise a recent review of spinal cord stimulation (SCS) in the treatment of low...
Mainstay announces publication detailing economic impact of restorative neurostimulation
Mainstay Medical has announced the publication of a paper, titled “Effect of Restorative Neurostimulation on Major Drivers of Chronic Low Back Pain Economic Impact",...
High-frequency spinal cord stimulation may be associated with “significant decrease” in...
High-frequency spinal cord stimulation (HF-SCS) for treating chronic refractory low back pain (CRLBP) may be associated with a significant decrease in total healthcare costs,...
SynerFuse announces “milestone” solo spine surgeon procedure in DRG stimulation study
Justin Zenanko, the CEO of SynerFuse, announced today that—in what the company says is a world-first—a solo spine surgeon has performed the “groundbreaking” SynerFuse...
Mainstay announces publication of post-market data from ongoing chronic low back...
Mainstay Medical has announced the publication of data from a single-centre, real-world study with one-year clinical follow-up of patients selected from its ReActiv8-C study,...
UK NICE publishes interventional procedure guidance for ReActiv8 restorative neurostimulation
Mainstay Medical has announced that the National Institute for Health and Care Excellence (NICE), a public body of the UK Department of Health, has...
First patient implanted in integrated spinal fusion and DRG stimulation proof-of-concept...
SynerFuse has announced the first implantation in the company's proof-of-concept study evaluating the safety and tolerability of simultaneously implanting spinal fusion hardware and a dorsal...
Mainstay Medical announces positive efficacy and safety outcomes from ReActiv8-B trial
Mainstay Medical has announced the publication of two-year patient outcomes data from its pivotal ReActiv8-B clinical trial. The data, which are published in Neuromodulation:...
CRISP study indicates clinical benefit of non-paraesthesia-based approaches in burst SCS...
The CRISP (Comparison of paraesthesia mapping to anatomic midline-based burst programming strategies) study, published in Neuromodulation: Technology at the Neural Interface, has found that...
DTM SCS: A unique, tailored and highly effective therapy option for...
Michael Fishman (Wilmington, USA) discusses the benefits of Differential Target Multiplexed spinal cord stimulation (DTM SCS; Medtronic)—when compared to more conventional SCS therapy options—and...
Mainstay Medical launches implantable restorative neurostimulation system in USA
Mainstay Medical has announced the limited US commercial launch of ReActiv8, its implantable restorative neurostimulation system to treat intractable chronic low back pain. The...
Study shows “major energy savings” can be achieved in spinal cord...
The results of the HALO (High and low frequency options) study, which are published online in the scientific journal Neuromodulation: Technology at the Neural...
Real-world review reports significant reduction in pain with high-frequency 10kHz SCS
A multicentre real-world review of 10kHz of spinal cord stimulation (SCS) for the treatment of chronic back and leg pain has elicited positive results,...
Mainstay Medical announces headline results from ReActiv8-B clinical study
Mainstay Medical International, a medical device company focused on commercialising ReActiv8, an implantable restorative neurostimulation system designed to treat an underlying cause of disabling...
Radiofrequency denervation fails to provide clinically important chronic low back pain...
In three randomised trials, treatment of chronic low back pain (CLBP) with radiofrequency denervation resulted in either no improvement or no clinically important improvement...
